Product Description
Cladribine is used to treat hairy cell leukemia (cancer of a certain type of white blood cell). Cladribine is in a class of medications known as purine analogs. It works by stopping or slowing the growth of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a693015.html)
Mechanisms of Action: TK Inhibitor,ADA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting
Known Adverse Events: Headache | Lymphopenia | Respiratory Tract Infections
Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, France, Georgia, Germany, Greece, Ireland, Italy, Japan, Korea, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Histiocytosis|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Relapsing-Remitting|Muscle Weakness|Myasthenia Gravis
Phase 2: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Biphenotypic Acute Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders|Preleukemia
Phase 1: Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MS700568_0183 | P3 |
Unknown Status |
Myasthenia Gravis |
2031-02-28 |
|
| jRCT2031240175 | P3 |
Not yet recruiting |
Myasthenia Gravis |
2031-02-28 |
|
| MyClad | P3 |
Recruiting |
Muscle Weakness|Myasthenia Gravis |
2028-05-19 |
|
| MCC-23154 | P2 |
Not yet recruiting |
Acute Myeloid Leukemia |
2027-11-01 |